IQVIA Biotech’s Post

PAH clinical trials face incredibly unique hurdles, but the treatment landscape is shifting! From cutting-edge drug therapies to reimagined clinical trial designs, explore how innovative approaches are shaping the future of cardiovascular health. Dive into the latest insights here: https://bit.ly/4ae46NG #PAH #PatientCare #HealthInnovation

The GLP-1 craze is not just a flash in the pan. This week, results from the longest semaglutide (Ozempic/Wegovy) clinical trial data were published in Nature Magazine. Here are a few highlights: - Weight loss continued through 65 weeks and was sustained for up to 208 weeks - A reduced risk of cardiovascular events was observed across the study population, regardless of how much weight was lost - Cardiac benefits are not driven by weight loss alone With the ongoing publication of robust clinical trial data, the long-term staying power of GLP-1 medications will be solidified as a primary therapeutic option for many patients. Source: https://lnkd.in/d3_Ej6Ws

🚀 Exciting Progress in MS Treatment! 🚀 I’m thrilled to see the FDA’s approval of Roche’s Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) – a huge step forward for those living with multiple sclerosis. With just two quick injections a year, this subcutaneous option makes it easier for patients to manage their treatment without lengthy infusion sessions, all while offering the same efficacy. It’s amazing how these innovations not only improve treatment outcomes but also empower patients by giving them more time and flexibility. This is a powerful reminder of how even small shifts in healthcare can make a life-changing difference. Kudos to the teams driving such advancements! If you’re passionate about healthcare or know someone who could benefit from learning more about MS advancements, feel free to connect. #MSTreatment #HealthcareInnovation #OcrevusZunovo #PatientEmpowerment

🚀 Exciting News in MS Treatment! 🚀 Roche’s Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) just received FDA approval for adults with relapsing and primary progressive multiple sclerosis (MS)! This new subcutaneous formulation could be a real game-changer, offering a faster and more convenient option than traditional IV infusions. So, what makes Ocrevus Zunovo different? 💉 Quick Subcutaneous Injection: Administered just twice a year in under five minutes, reducing the need for extended IV infusion sessions and making treatment more accessible for MS patients. 🕒 Saves Time & Increases Comfort: This new formulation is expected to cut infusion time while still delivering the same level of efficacy and safety as the IV version. 🎯 Targeted Therapy: Works by targeting CD20-positive B-cells, which play a role in the immune system attacks on myelin, the protective layer around nerve fibers in the central nervous system. This approval reflects a growing commitment to making chronic disease management easier and improving patients' quality of life through more flexible treatment options. This breakthrough reaffirms the importance of innovation in healthcare, where even slight adjustments can make a significant impact on patient experience. If you’re interested in learning more about advancements in MS treatment or know someone who could benefit, let’s connect! #OcrevusZunovo #MultipleSclerosis #MSAwareness #PatientCare #HealthInnovation #FDAApproval #Roche #Pharma

Hypertrophic cardiomyopathy (HCM) is often underdiagnosed and inconsistently managed. The American Heart Association is working on a new effort to improve and streamline how patients are identified, assessed, referred and treated. The three-year initiative, supported by Bristol Myers Squibb, will include a national HCM registry to collect and analyze data, a certification program to set standards of care, national education activities and more.

We live in an era where advancements in data science are transforming patient outcomes like never before. The American Heart Association HCM Registry, Recognition, and Site Certification Initiative is a prime example, providing insights into the detection, diagnosis, and treatment of hypertrophic cardiomyopathy (HCM) to empower healthcare providers.    HCM can be a serious heart condition, yet most people with HCM don’t know they have it. At BMS, we are proud to support efforts that leverage data to redefine what’s possible in cardiovascular care.     #BMS_Employee #ProudToBeBMS 

https://lnkd.in/ePxQBVAm As a #BMS_Employee I am thrilled to share our support of American Heart Association HCM Registry, Recognition, and Site Certification Initiative. Hypertrophic cardiomyopathy (HCM) is a lifelong disease that can worsen over time and initiatives like this will help standardize and facilitate evidence-based care for these patients.     I encourage you to learn more about the HCM systems of care initiative and the impact it will have for patient care.

A Personalized Approach to Endotoxic Septic Shock At Spectral Medical, we are committed to revolutionizing the treatment of Endotoxic Septic Shock (ESS)—a life-threatening condition affecting over 120,000 people in the U.S. annually. Septic shock continues to be one of the most challenging conditions in critical care. Our solution combines: ✅ The EAA™ Diagnostic Test: Accurately identifies endotoxin activity. ✅ Toraymyxin™ PMX Hemoperfusion: Removes harmful endotoxins from the bloodstream to help reduce inflammation and improve organ function. By combining our precise Endotoxin Activity Assay (EAA™) diagnostic test with the innovative PMX Hemoperfusion therapy, we target the root cause of endotoxemia, potentially improving outcomes for critically ill patients. Toraymyxin™ is currently in a Phase 3 clinical trial (The Tigris Trial) in the U.S. Learn more👉 https://buff.ly/49IBoV0 #Sepsis #CriticalCare #EndotoxicSepticShock

Our discrete choice experiment found that European gastroenterologists incorporated 7 efficacy, adverse event, and mode of administration attributes into their treatment decision-making when escalating patients with moderate-to-severe ulcerative colitis to their first advanced therapy. Probability of remission at 1-year had the strongest influence on gastroenterologists’ decision-making, and it was about 5 times more important as the next attribute 5-year risk of malignancy. “Understanding gastroenterologist preferences at the time of treatment escalation to first-line advanced therapies in ulcerative colitis: A discrete choice experiment conducted in five European countries” was presented at the United European Gastroenterology 2024 Conference in Berlin, Germany.

(4/9) PI3Kα-Driven Vascular Malformations is the first of two programs in #geneticdisease that we unveiled today. #Vascularmalformations are a series of rare syndromes that occur due to atypical development of lymphatic and/or blood vessels, of which mutant PI3Kα is the most common driver. There are over ~170,000 patients with PI3Kα-driven vascular malformations in the U.S. We believe our mutant-selective PI3Kα inhibitor, RLY-2608, provides the opportunity for greater target coverage, leading to the potential for improved efficacy and better chronic tolerability for these patients. We plan to initiate clinical development in Q1 2025.